Biocryst Pharmaceuticals (BCRX) Debt to Equity: 2011-2015
Historic Debt to Equity for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to $0.47.
- Biocryst Pharmaceuticals' Debt to Equity was N/A to $0.47 in Q3 2015 from the same period last year, while for Sep 2015 it was $1.87, marking a year-over-year change of. This contributed to the annual value of $0.40 for FY2014, which is 101.49% up from last year.
- As of Q3 2015, Biocryst Pharmaceuticals' Debt to Equity stood at $0.47, which was up 18.81% from $0.39 recorded in Q2 2015.
- In the past 5 years, Biocryst Pharmaceuticals' Debt to Equity ranged from a high of $8.80 in Q3 2013 and a low of -$66.08 during Q4 2012.
- Its 3-year average for Debt to Equity is -$3.92, with a median of $0.39 in 2015.
- As far as peak fluctuations go, Biocryst Pharmaceuticals' Debt to Equity tumbled by 3,361.23% in 2012, and later surged by 186.92% in 2013.
- Biocryst Pharmaceuticals' Debt to Equity (Quarterly) stood at $2.03 in 2011, then slumped by 3,361.23% to -$66.08 in 2012, then spiked by 59.68% to -$26.64 in 2013, then spiked by 101.49% to $0.40 in 2014, then spiked by 108.89% to $0.47 in 2015.
- Its Debt to Equity stands at $0.47 for Q3 2015, versus $0.39 for Q2 2015 and $0.47 for Q1 2015.